Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LCTX stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Michael Okunewitch has given his Buy rating due to a combination of factors surrounding Lineage Cell Therapeutics’ promising developments and strategic partnerships. The company reported a manageable net loss and maintains a healthy cash reserve, which is expected to support its ongoing operations and research initiatives. A significant factor is the continued progress in the OpRegen program, particularly with the involvement of Genentech (Roche), which is actively enrolling participants in its P2a optimization study. This collaboration and the introduction of novel surgical devices underscore Roche’s commitment to the program, indicating confidence in OpRegen’s potential as a one-time therapy for geographic atrophy.
Additionally, the initiation of the DOSED study for OPC1, aimed at treating spinal cord injuries, marks a critical step forward. The study, which includes functional assessments, offers Lineage an opportunity to explore new therapeutic settings. The potential for efficacy in treating spinal cord injuries, combined with the lack of existing options, suggests that even modest positive outcomes could lead to further exploration and development. These strategic advancements and partnerships highlight Lineage’s potential for growth and innovation, justifying the Buy rating.
LCTX’s price has also changed dramatically for the past six months – from $0.885 to $0.458, which is a -48.25% drop .